{
  "id": 3264997,
  "title": "THE CONVERSATION: Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread",
  "url": "https://urgent.news/2026/08/25/the-conversation-can-ozempic-prevent-cancer-a-doctor-explains-why-the",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-25T13:02:16.000Z",
  "source": {
    "name": "Daily Maverick",
    "slug": "daily-maverick",
    "url": "https://www.dailymaverick.co.za/article/2026-08-25-can-ozempic-prevent-cancer-a-doctor-explains-why-the-headlines-are-easy-to-misread/"
  },
  "original_language": "en",
  "account": "The conversation surrounding Ozempic's potential cancer-preventing abilities has sparked a heated debate. Observational studies suggest a link between GLP-1 drugs like Ozempic and lower rates of certain cancers, but health experts warn that the headlines surrounding this claim are misleading.\n\nGLP-1 drugs, which include Ozempic, have been linked to lower rates of some cancers, but the studies are filled with pitfalls that could skew the results. Healthy-user bias is a major factor, as people who start GLP-1 drugs are often healthier and wealthier than those who don't. This means that their lower cancer rates may be attributed to better overall health, not the drug itself.\n\nAnother complication is the choice of comparison drug. The studies comparing GLP-1 drugs to insulin or metformin may not accurately reflect the drug's true effects, as these diabetes treatments are often prescribed to people with a higher risk of cancer.\n\nLastly, the timeframe for observing cancer risk is problematic. Cancer can take decades to develop, but most GLP-1 studies only follow patients for a few years. This makes it difficult to accurately determine the drug's long-term impact on cancer risk.\n\nDespite these challenges, some studies suggest that GLP-1 drugs may have a preventative effect on cancer. For example, a 2024 study found lower rates of 10 out of 13 obesity-related cancers in people treated with GLP-1 drugs compared to those on insulin. Another study found that overall cancer rates among GLP-1 users were roughly 17% lower, with significant reductions in endometrial, ovarian, and meningioma cancers.",
  "summary": "GLP-1 drugs like Ozempic appear linked to lower rates of some cancers in observational studies, yet healthy-user bias and short follow-up mean prevention remains unproven.",
  "key_points": [
    "GLP-1 drugs like Ozempic linked to lower rates of certain cancers in observational studies.",
    "Healthy-user bias and choice of comparison drugs complicate the interpretation of study results."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}